Carregant...
Radiopharmaceuticals for Relapsed or Refractory Ovarian Cancers
Targeted radiopharmaceuticals for therapeutic use deliver radionuclides directly to tumor anywhere in the body, and therefore, have renewed interest for clinical development in women with disseminated chemorefractory ovarian cancers. About two in every five women with advanced stage ovarian cancer o...
Guardat en:
| Publicat a: | Front Oncol |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6448015/ https://ncbi.nlm.nih.gov/pubmed/30984615 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00180 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|